Nigel Mackman Selected Research

Nigel Mackman Research Topics

Disease

83	Thrombosis (Thrombus) 11/2022 - 03/2003
50	Neoplasms (Cancer) 11/2022 - 02/2005
36	Inflammation (Inflammations) 01/2022 - 10/2003
20	Hemorrhage 07/2022 - 04/2005
20	Venous Thrombosis (Deep-Vein Thrombosis) 01/2022 - 02/2009
19	Infections 11/2021 - 03/2003
13	Venous Thromboembolism 07/2022 - 12/2006
12	Pancreatic Neoplasms (Pancreatic Cancer) 05/2022 - 06/2012
11	Atherosclerosis 01/2022 - 07/2002
10	Sepsis (Septicemia) 05/2021 - 08/2002
10	Endotoxemia 02/2017 - 01/2003
9	COVID-19 02/2022 - 01/2020
9	Ischemia 01/2022 - 02/2003
8	Atherosclerotic Plaque (Atheroma) 01/2020 - 08/2005
7	Rupture 01/2018 - 03/2003
6	Virus Diseases (Viral Diseases) 11/2021 - 05/2008
6	Neoplasm Metastasis (Metastasis) 06/2019 - 02/2005
6	Infarction (Infarctions) 01/2018 - 02/2003
6	Hypoxia (Hypoxemia) 11/2017 - 03/2003
6	Reperfusion Injury 11/2017 - 02/2003
5	Disseminated Intravascular Coagulation 11/2021 - 01/2003
5	Glioma (Gliomas) 01/2021 - 07/2006
5	Heart Failure 01/2021 - 11/2007
5	Necrosis 01/2018 - 03/2009
5	Sickle Cell Anemia (Hemoglobin S Disease) 11/2017 - 07/2012
5	Cardiovascular Diseases (Cardiovascular Disease) 01/2017 - 10/2003
4	Thromboembolism 05/2022 - 01/2010
4	Coronary Artery Disease (Coronary Atherosclerosis) 01/2022 - 02/2012
4	Fibrosis (Cirrhosis) 01/2021 - 03/2007
4	Myocardial Infarction 01/2018 - 11/2007
3	Hypertrophy 01/2021 - 11/2007
3	Breast Neoplasms (Breast Cancer) 01/2020 - 01/2010
3	Stroke (Strokes) 01/2020 - 07/2016
3	Hyperlipidemias (Hyperlipidemia) 01/2015 - 05/2012
3	Glioblastoma (Glioblastoma Multiforme) 11/2014 - 07/2006

Drug/Important Bio-Agent (IBA)

127	Thromboplastin (Tissue Factor)IBA 11/2022 - 07/2002
33	Thrombin FDA Link 01/2022 - 02/2003
27	Proteins (Proteins, Gene)FDA Link 11/2022 - 03/2003
22	FibrinIBA 05/2021 - 01/2003
20	AnticoagulantsIBA 01/2022 - 02/2004
20	Biomarkers (Surrogate Marker)IBA 11/2021 - 03/2009
13	Peptide Hydrolases (Proteases)FDA Link 01/2021 - 02/2004
12	fibrin fragment D (D-dimer)IBA 11/2021 - 07/2012
11	Hemostatics (Antihemorrhagics)IBA 01/2022 - 03/2006
9	CytokinesIBA 01/2020 - 02/2003
9	LipopolysaccharidesIBA 01/2019 - 08/2002
9	Proteinase-Activated ReceptorsIBA 01/2019 - 02/2004
7	Messenger RNA (mRNA)IBA 11/2021 - 03/2003
7	Factor VIIa (Activated Factor VII)IBA 01/2020 - 05/2004
6	Factor Xa (Coagulation Factor Xa)IBA 01/2022 - 09/2012
6	AntithrombinsIBA 01/2022 - 12/2006
6	Interleukin-6 (Interleukin 6)IBA 10/2021 - 05/2004
6	Fibrinogen (Factor I)FDA Link 01/2021 - 05/2003
6	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2015 - 10/2008
5	LDL Receptors (LDL Receptor)IBA 01/2022 - 03/2006
5	AntibodiesIBA 11/2021 - 10/2007
5	Plasminogen Activator Inhibitor 1IBA 10/2021 - 10/2011
5	Plasminogen Activators (Plasminogen Activator)IBA 01/2021 - 11/2006
5	NF-kappa B (NF-kB)IBA 08/2009 - 08/2002
4	RivaroxabanIBA 01/2022 - 01/2018
4	RNA (Ribonucleic Acid)IBA 11/2021 - 04/2014
4	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 10/2021 - 08/2002
4	Monoclonal AntibodiesIBA 01/2021 - 02/2003
4	Histones (Histone)IBA 11/2020 - 12/2019
4	ferric chlorideIBA 05/2020 - 01/2009
4	Complement System Proteins (Complement)IBA 01/2020 - 10/2007
4	LipidsIBA 01/2020 - 09/2005
4	Transcription Factors (Transcription Factor)IBA 06/2019 - 08/2002
4	PAR-2 ReceptorIBA 06/2019 - 10/2008
4	Pharmaceutical PreparationsIBA 01/2018 - 05/2009
4	estropipate (Ogen)FDA LinkGeneric 08/2017 - 05/2003
4	P-SelectinIBA 01/2017 - 12/2006
4	PolyphosphatesIBA 04/2016 - 04/2014
4	ChemokinesIBA 01/2011 - 02/2003
3	Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA 01/2022 - 09/2015
3	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2022 - 09/2015
3	Factor Xa InhibitorsIBA 01/2022 - 01/2018
3	Apolipoproteins E (ApoE)IBA 01/2022 - 03/2006
3	ApolipoproteinsIBA 01/2022 - 03/2006
3	Fibrinolysin FDA Link 05/2021 - 01/2021
3	InterferonsIBA 01/2021 - 05/2008
3	Glycoproteins (Glycoprotein)IBA 01/2020 - 09/2005
3	Factor XIa (Coagulation Factor XIa)IBA 01/2020 - 04/2016
3	IntegrinsIBA 06/2019 - 04/2013
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 06/2019 - 03/2003
3	Antiphospholipid AntibodiesIBA 02/2019 - 10/2008
3	Factor XI (Plasma Thromboplastin Antecedent)IBA 01/2019 - 08/2011
3	AnthracyclinesIBA 01/2018 - 07/2010
3	CholesterolIBA 01/2018 - 02/2012
3	PAR-1 ReceptorIBA 01/2018 - 11/2011
3	Factor XII (Hageman Factor)IBA 09/2015 - 04/2012
3	oxidized low density lipoproteinIBA 01/2015 - 02/2012
3	epidermal growth factor receptor VIIIIBA 11/2014 - 12/2008
3	Biological ProductsIBA 05/2014 - 03/2009
3	Antiviral Agents (Antivirals)IBA 04/2014 - 05/2008
3	CoagulantsIBA 04/2014 - 07/2012
3	Transcription Factor AP-1 (Transcription Factor AP 1)IBA 03/2009 - 08/2002

Therapy/Procedure

21	Therapeutics 01/2022 - 05/2003
8	Drug Therapy (Chemotherapy) 11/2021 - 01/2010
7	Ligation 01/2021 - 07/2002